Company AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:05 11/12/2024 GMT			5-day change	1st Jan Change
10,538.00 ^GBX	+0.25%		+0.55%	-0.58%

12-11	Merck and AstraZeneca unveil long-term Lynparza results	AN
12-11	AstraZeneca, Merck's Lynparza Shows Prolonged Survival Benefit in Early Breast Cancer Patients	MT

Business description: AstraZeneca PLC

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:

- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);

- collaboration revenue (4.4%).

Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Number of employees: 89,900

Sales by Activity: AstraZeneca PLC

Fiscal Period: December	2019	2020	2021	2022	2023
Biopharmaceuticals	24.38B	26.62B	37.42B	44.35B	45.81B

See all business segments

Geographical breakdown of sales: AstraZeneca PLC

Fiscal Period: December	2019	2020	2021	2022	2023
United States	8.05B	8.96B	12.05B	17.28B	18.12B
China	4.87B	5.34B	6B	5.74B	5.87B
Japan	2.52B	2.57B	3.4B	3.99B	3.64B
United Kingdom	1.82B	1.74B	3.24B	3.12B	3.37B
Other Rest of Europe	1.29B	1.39B	1.95B	2.71B	3.11B
Germany	704M	937M	1.49B	1.9B	2.1B
Other Asia, Africa & Australasia	1.42B	1.53B	2.38B	2.41B	2.04B
Sweden	834M	1.03B	2.32B	1.72B	1.7B
Other Americas	814M	761M	1.2B	1.18B	1.68B
France	578M	653M	915M	1.11B	1.15B
Canada	466M	596M	772M	1.17B	967M
Spain	359M	398M	578M	738M	847M
Italy	396M	431M	577M	735M	813M
Australia	266M	282M	547M	571M	390M

See all geographic segments

Managers: AstraZeneca PLC

Director	Title	Age	Since
Pascal Soriot CEO	Chief Executive Officer	64	30/09/2012
Aradhana Sarin DFI	Director of Finance/CFO	50	31/07/2021
Cindy Hoots CTO	Chief Tech/Sci/R&D Officer	56	31/12/2019
Sharon Barr CTO	Chief Tech/Sci/R&D Officer	-	31/07/2023
Alberto Hegewisch CTO	Chief Tech/Sci/R&D Officer	-	17/05/2023

See ASTRAZENECA PLC governance

Members of the board: AstraZeneca PLC

Manager	Title	Age	Since
Marcus Wallenberg BRD	Director/Board Member	68	05/04/1999
Pascal Soriot BRD	Director/Board Member	64	30/09/2012
Philip Broadley BRD	Director/Board Member	63	26/04/2017
Nazneen Rahman BRD	Director/Board Member	-	31/05/2017
Sherilyn McCoy BRD	Director/Board Member	66	30/09/2017
Deborah DiSanzo BRD	Director/Board Member	64	30/11/2017
Shu Kam Mok BRD	Director/Board Member	63	31/12/2018
Michel Demaré CHM	Chairman	68	26/04/2023
Euan Ashley BRD	Director/Board Member	-	30/09/2020
Diana Layfield BRD	Director/Board Member	-	31/10/2020

Composition of the Board of Directors

Shareholders: AstraZeneca PLC

Name	Equities	%	Valuation
BlackRock Investment Management (UK) Ltd. 4.419 %	68,512,693	4.419 %	9 241 M p
Wellington Management Co. LLP 4.201 %	65,120,892	4.201 %	8 784 M p
The Vanguard Group, Inc. 3.661 %	56,762,000	3.661 %	7 656 M p
Investor AB (Investment Company) 3.328 %	51,587,810	3.328 %	6 958 M p
Norges Bank Investment Management 2.071 %	32,107,000	2.071 %	4 331 M p

Name	Equities	%	Valuation
T. Rowe Price International Ltd. 2.028 %	62,892,582	2.028 %	4 253 M p
PRIMECAP Management Co. 1.354 %	41,980,045	1.354 %	2 839 M p
Wellington Trust Co., NA 1.201 %	37,247,083	1.201 %	2 519 M p
Capital Research & Management Co. (International Investors) 1.188 %	36,821,151	1.188 %	2 490 M p
Fidelity Management & Research Co. LLC 0.7453 %	23,110,253	0.7453 %	1 563 M p

Name	Equities	%	Valuation
Caixa DTVM SA 0.002876 %	267,643	0.002876 %	3 M p

List of ASTRAZENECA PLC shareholders

Holdings: AstraZeneca PLC

Name	Equities	%	Valuation
ASTRAZENECA PHARMA INDIA LIMITED 75.00%	18,750,000	75.00%	1,456,152,000 $
SWEDISH ORPHAN BIOVITRUM AB 9.84%	35,043,624	9.84%	970,540,876 $
NIOX GROUP PLC 16.61%	66,093,108	16.61%	52,924,717 $
CELLECTIS S.A. 15.98%	16,000,000	15.98%	32,615,520 $
INNATE PHARMA 9.25%	7,485,500	9.25%	11,258,417 $
MONOPAR THERAPEUTICS INC. 7.34%	387,329	7.34%	8,726,522 $
CONDUIT PHARMACEUTICALS INC. 8.14%	9,504,465	8.14%	1,016,978 $

Company details: AstraZeneca PLC

AstraZeneca PLC

Cambridge Biomedical Campus 1 Francis Crick Avenue

CB2 0AA, Cambridge

+44 20 3749 5000

http://www.astrazeneca.co.uk

Group companies: AstraZeneca PLC

Name	Category and Sector
Astrazeneca Treasury BV
AstraZeneca AB AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.	Miscellaneous Commercial Services
AstraZeneca Employee Share Trust Ltd. AstraZeneca Employee Share Trust Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AstraZeneca PLC, AstraZeneca Employee Share Trust Ltd. is a British company that provides business support services. The company is located in the UK.	Miscellaneous Commercial Services
AstraZeneca UK Ltd. AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom.	Miscellaneous Commercial Services
Alexion Pharmaceuticals, Inc. /New/

See all subsidiaries

Other Pharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ASTRAZENECA PLC	+0.25%	+0.55%	+4.38%	+28.62%	208B
ELI LILLY AND COMPANY	-0.44%	-4.07%	+36.30%	+226.05%	720B
NOVO NORDISK A/S	+1.00%	+1.32%	+18.10%	+110.47%	488B
JOHNSON & JOHNSON	-1.74%	-2.55%	-5.43%	-11.39%	359B
ABBVIE INC.	-0.74%	-1.18%	+15.29%	+38.97%	310B
MERCK & CO., INC.	-1.24%	-1.60%	-4.43%	+37.36%	255B
ROCHE HOLDING AG	+0.83%	+0.87%	+0.63%	-32.12%	231B
NOVARTIS AG	-0.92%	-2.40%	+2.76%	+17.79%	201B
AMGEN INC.	-0.85%	-1.74%	+0.47%	+29.65%	148B
PFIZER, INC.	-1.33%	0.00%	-11.91%	-52.20%	145B
Average	-0.10%	-1.46%	+5.62%	+39.32%	306.61B
Weighted average by Cap.	-0.05%	-1.83%	+11.93%	+76.03%